Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
髓源性抑制细胞在胶质母细胞瘤局部和全身免疫抑制中的作用
基本信息
- 批准号:10746880
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-07 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressAdoptive TransferAttenuatedBehaviorBiologicalBlood VesselsBone MarrowCAR T cell therapyCancer VaccinesCell LineageCell ProliferationCellsChimera organismCirculationClinical TrialsComplementDevelopmentDiseaseDisease OutcomeFemaleFoundationsFrequenciesGene Expression ProfileGenerationsGerm CellsGlioblastomaGrowthImmune EvasionImmune checkpoint inhibitorImmune responseImmunityImmunosuppressionImmunotherapeutic agentImmunotherapyImpairmentIn VitroIncidenceIndividualInfiltrationInterleukin-1 betaInterventionKnock-outLaboratoriesLeftMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMediatingMediatorMusMyeloid-derived suppressor cellsOX40Oncolytic virusesPathogenesisPathway AnalysisPathway interactionsPatient-Focused OutcomesPatientsPeripheralPharmaceutical PreparationsPhasePlayPopulation HeterogeneityPre-Clinical ModelPredispositionPrimary Brain NeoplasmsProductionPrognosisRegulationReportingResearchRoleSerumSex DifferencesT-Cell ActivationT-Lymphocyte and Natural Killer CellTestingTherapeuticTumor ImmunityTumor-associated macrophagesVariantantagonistanti-CTLA4anti-PD-1anti-tumor immune responseautocrinecancer stem cellchemotherapyclinical efficacyclinically relevantcomplement systemdensitydrug candidatedrug repurposingefficacy evaluationexperimental studyfludarabinegenetic signaturegranulocyteimmune activationimmune checkpointimprovedin vitro activityin vivoinhibitorinsightmalemonocyteneoplastic cellnovelpharmacologicpolarized cellprogramsreceptorresponsesexstandard of carestem cell self renewalsuccesstherapeutic targettherapy outcometherapy resistanttranscriptometreatment responsetumortumor growthtumor microenvironmenttumor progressiontumor-immune system interactionstumorigenesis
项目摘要
PROJECT SUMMARY: Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median
survival of up to 20 months. Males have a 1.6-fold higher incidence of GBM compared to females and worse
disease outcome. Standard-of-care treatment and immunotherapies, which are currently in clinical trials, have
had limited success improving patient outcome. An immunosuppressive microenvironment facilitating tumor
progression and restricting anti-tumor immune response likely underlies therapeutic resistance. Although
myeloid-derived suppressor cell (MDSCs) accumulate in patients with malignancies and play a critical role in the
establishment of this immunosuppressive milieu, the mechanisms by which individual MDSC subsets promote
tumorigenesis remain poorly defined. In pre-clinical models, I demonstrated that monocytic MDSCs (mMDSCs)
infiltrated tumor at higher rates in males, while granulocytic MDSCs (gMDSCs) were more abundant in the
peripheral circulation of females. Furthermore, there were more immunosuppressive myeloid cells in the tumors
of male patients and gMDSC gene signature associated with poor prognosis of female patients. MDSC subset
variation also determined sex-specific therapeutic response in preclinical models, including to fludarabine and
anti-IL-1β. I also established that complement component 1q (C1q) is highly expressed by gMDSCs and elevated
in females. Based on these observations, I hypothesize that MDSC subsets promote GBM progression via
distinct mechanisms in a sex-specific manner and that their targeting will improve the efficacy of T cell-activating
strategies. Specific Aim 1 will test the hypothesis that mMDSCs and gMDSCs have distinct roles in local and
systemic immunosuppression in a sex-specific manner. This aim will investigate the changes in tumor growth,
vascular density and immune activation status by adoptively transferring MDSC subsets and selectively depleting
MDSCs in bone marrow chimeras. Specific Aim 2 will test the hypothesis that the unique gene expression
signatures of MDSC subsets makes them susceptible to distinct drugs that can be combined with checkpoint
modulators. Sub-Aim 2A will examine the efficacy of drug candidates on MDSC activity in vitro and in vivo, while
Sub-Aim 2B will attempt to achieve durable anti-tumor immune response by combining MDSC targeting
strategies with anti-PD-1, anti-CTLA-4 and anti-OX40. Specific Aim 3 will test the hypothesis that gMDSC-
derived C1q promotes MDSC lineage commitment and systemic immunosuppression by evaluating tumor
progression and checkpoint response in the absence of C1q. Sub-Aim 3A will use C1qa knockout bone marrow
and C1q receptor inhibitors to determine MDSC fate. Sub Aim 3B will use pharmacological inhibitors combined
with checkpoint modulators. These studies lay the foundation for my future research program and the
development of novel immunotherapies for GBM by addressing variations in anti-tumor immunity, repurposing
drugs and defining targetable pathways. These results are broadly applicable to other cancers and can lead to
advanced treatment opportunities and improved patient outcome.
胶质母细胞瘤(GBM)是最常见的原发性恶性脑肿瘤,
生存期长达20个月。男性GBM的发病率是女性的1.6倍,
疾病结果。目前正在临床试验中的标准治疗和免疫疗法,
改善患者预后的成功率有限。免疫抑制微环境促进肿瘤
进展和限制抗肿瘤免疫应答可能是治疗抗性的基础。虽然
骨髓源性抑制细胞(MDSC)在恶性肿瘤患者中积累,并在肿瘤的发生和发展中起关键作用。
建立这种免疫抑制环境,单个MDSC亚群促进免疫抑制的机制,
肿瘤发生仍然定义不清。在临床前模型中,我证明了单核细胞MDSC(mMDSC)
在男性中,浸润性肿瘤的发生率更高,而粒细胞MDSC(gMDSC)在男性中更丰富。
女性的外周循环此外,肿瘤中有更多的免疫抑制性髓样细胞
gMDSC基因特征与女性患者预后不良相关。MDSC子集
变异还决定了临床前模型中的性别特异性治疗反应,包括对氟达拉滨和
抗IL-1β。我还确定了补体成分1 q(C1 q)在gMDSC中高度表达,并在GMDSC中升高。
在女性中。基于这些观察,我假设MDSC亚群通过以下途径促进GBM进展:
它们的靶向作用将改善T细胞活化的功效,
战略布局具体目标1将检验mMDSC和gMDSC在局部和局部分化中具有不同作用的假设。
以性别特异性方式进行全身免疫抑制。这一目标将研究肿瘤生长的变化,
通过过继转移MDSC亚群和选择性耗竭MDSC,
骨髓嵌合体中的MDSC。具体目标2将检验以下假设:
MDSC亚群的特征使其对可与检查点结合的不同药物敏感
调制器。子目标2A将检查候选药物在体外和体内对MDSC活性的功效,
子目标2B将尝试通过结合MDSC靶向,
抗PD-I、抗CTLA-4和抗0X 40的策略。具体目标3将检验gMDSC-
衍生C1 q通过评估肿瘤促进MDSC谱系定型和全身免疫抑制
C1 q缺失时的进展和检查点反应。子目标3A将使用C1 qa敲除骨髓
和C1 q受体抑制剂来确定MDSC的命运。子目标3B将联合使用药理学抑制剂
检查点调制器。这些研究为我今后的研究计划和
通过解决抗肿瘤免疫的变化,
药物和确定靶向途径。这些结果广泛适用于其他癌症,并可能导致
先进的治疗机会和改善的患者结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Defne Bayik Watson其他文献
Defne Bayik Watson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Defne Bayik Watson', 18)}}的其他基金
Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
髓源性抑制细胞在胶质母细胞瘤局部和全身免疫抑制中的作用
- 批准号:
10837997 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
髓源性抑制细胞在胶质母细胞瘤局部和全身免疫抑制中的作用
- 批准号:
10323691 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant